Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries
Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Georges‐Philippe Pageaux(Goethe University Frankfurt), Ioannis Goulis, Olivier Clerc(Brigham and Women's Hospital), Ariel Porcalla, Ella Veitsman, Yves Horsmans(Cliniques Universitaires Saint-Luc), Robert Flisiak(Medical University of Białystok), Zhenzhen Zhang, Nuno Marques(Hospital do Espírito Santo), Harald Hofer(Klinikum Wels-Grieskirchen), Mark Bondin
Cited by 2
Related Papers
Simplified criteria for the diagnosis of autoimmune hepatitis†
|Hepatology|2008|1.9k
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma
|Transplantation|2015|417
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
|Journal of Hepatology|2019|364
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346